Oxyphenbutazone

DB03585ApprovedWithdrawnSmall molecule

Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) no longer commonly used for the symptomatic relief of musculoskeletal pain. Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

Chemical structure of Oxyphenbutazone
Mechanism
Curator reviewed
Formula / weight
C19H20N2O3 · 324.3737 g/mol (avg)
First approval
Canada, 1997
Also known as
Oxiphenbutazone
Code names
USAF Ge-14

Resolves to

Compound
UNIIA7D84513GVCAS129-20-4ChEMBLCHEMBL1228ChEBI76258PubChem4641KEGGC19494
Clinical / RWD
RxNorm7816ATCM01AA03ATCM02AA04ATCS01BC02PharmGKBPA450750
Structure
InChIKeyHFHZKZSRXITVMK-UHFFFAOYSA-NSMILESCCCCC1C(=O)N(N(C1=O)C1=CC=C(O)C=C1)C1=CC=CC=C1
Targets
P02768ALBQ9NZK7PLA2G2E
Transporters
Q4U2R8SLC22A6

What you can answer from here — as of September 12, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
1,406Drug interactionsStructured to mechanism, not free text
Sign in
2Marketed productsAcross 1 country and 2 labellers
Sign in
3ATC codesIncluding every combination product, plus 23 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Oxyphenbutazone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In